Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
Globe Newswire•03/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 net revenue $37.8 million, up 45% year over year
- ➤MIPLYFFA generated $34.0 million in Q3 net revenue
- ➤Q3 net income $19.2 million, versus $0.5 million loss
- ➤Cash, equivalents and investments totaled $270.9 million September 30
- ➤Zevra expects filing MIPLYFFA infant-use sNDA in Q1 2027
Expert Statements
Neil F. McFarlane, President and Chief Executive Officer of Zevra Therapeutics
“In the third quarter, we made continued progress across our business, building on MIPLYFFA's commercial performance in the U.S. and advancing our pipeline in support of our mission to redefine what’s possible in bringing life-changing therapies to people living with rare disease.”
Neil F. McFarlane, President and Chief Executive Officer of Zevra Therapeutics
“We remain focused on reaching more people living with Niemann-Pick disease type C, advancing celiprolol for vascular Ehlers-Danlos syndrome, and pursuing European access to arimoclomol.”
Neil F. McFarlane, President and Chief Executive Officer of Zevra Therapeutics
“Our strong financial position enables us to advance these priorities while continuing to make arimoclomol available to eligible patients through our global Expanded Access Program.”
$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA
Operational execution fueled strong cash position of $270.9 million
Get started
Create a free account to read the full story.